文献速递肿瘤 PET/CT心脏核医学放射性药物与辐射防护

18F-氟比他班全身PET/CT早期检测多器官轻链淀粉样变性

Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET/CT.
PubMed 文献 · J Nucl Med · 2019-04-06

该前瞻性研究纳入40例活检证实的AL淀粉样变性患者(30例活动期,10例血液学缓解>1年),行18F-florbetapir PET/CT。与国际化共识定义相比,PET/CT在腮腺、舌、肺等器官检出淀粉样沉积的比例更高,但在肾和腹壁脂肪更低;定量分析较视觉分析在多个器官检出更频繁。结论认为PET/CT可检测活动期和缓解期患者的广泛器官沉积,多数沉积无症状且未被识别。

要点

  • 18F-florbetapir PET/CT可在AL淀粉样变性患者中检出多器官淀粉样沉积。
  • 与共识定义相比,PET/CT对腮腺、舌、肺的受累检出率更高。
  • 定量分析较视觉分析在舌、甲状腺、肺、胰腺、肾、肌肉和肱骨头检出更频繁。

核心结论

  • 18F-florbetapir PET/CT在活动期和血液学缓解的AL淀粉样变性患者中均检出广泛器官淀粉样沉积。
  • 多数器官的淀粉样沉积与临床症状不相关,因而未被识别。

研究设计与样本

  • 前瞻性研究纳入40例活检证实的AL淀粉样变性患者,其中活动期30例、血液学缓解超过1年10例。
  • 所有受试者行18F-florbetapir PET/CT,扫描范围从颅底至肾下,注射放射性示踪剂后60至90分钟采集。

主要发现

  • 与国际化共识定义相比,PET/CT检出腮腺受累比例为50%对3%,舌为53%对10%,肺为35%对10%。
  • 与国际化共识定义相比,PET/CT检出肾受累比例为13%对28%,腹壁脂肪为10%对13%。
  • 定量分析较视觉分析在舌、甲状腺、肺、胰腺、肾、肌肉和肱骨头检出器官受累更频繁。

关键数值与推荐

  • 除肝脏外,所有器官SUVmax至少2.5视为异常。
  • 各器官摄取通过视觉与脊柱骨髓摄取进行比较。

临床怎么用

  • 18F-florbetapir PET/CT可能有助于早期识别系统性器官受累,从而辅助制定治疗决策。
  • 无创监测器官层面病变可能指导新型纤维溶解疗法的管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin light-chain (AL) amyloidosis affects multiple systemic organs. However, determination of the precise extent of organ involvement remains challenging. Targeted amyloid imaging with 18F-florbetapir PET/CT offers the potential to detect AL deposits in multiple organs. The primary aim of this study was to determine the distribution and frequency of AL deposits in the various organs of subjects with systemic AL amyloidosis using 18F-florbetapir PET/CT. Methods: This prospective study included 40 subjects with biopsy-proven AL amyloidosis including active AL amyloidosis (n = 30) or AL amyloidosis in hematologic remission for more than 1 y (n = 10). All subjects underwent 18F-florbetapir PET/CT, skull base to below the kidney scan field, from 60 to 90 min after injection of radiotracer. Volume-of-interest measurements of SUVmax were obtained using Hermes software for the parotid gland, tongue, thyroid, lung, gastric wall, pancreas, spleen, kidney, muscle, abdominal fat, lower thoracic spine, vertebral body, and humeral head. Uptake in each organ was visually compared with that in spine bone marrow. An SUVmax of at least 2.5 was considered abnormal in all organs other than the liver. Results: Compared with the international consensus definition of organ involvement, 18F-florbetapir PET/CT identified amyloid deposits in substantially higher percentages of subjects for several organ systems, including parotid gland (50% vs. 3%), tongue (53% vs. 10%), and lung (35% vs. 10%). In several organ systems, including kidney (13% vs. 28%) and abdominal wall fat (10% vs. 13%), PET identified involvement in fewer subjects than did international consensus. Quantitative analysis of 18F-florbetapir PET/CT revealed more frequent organ involvement than did visual analysis in the tongue, thyroid, lung, pancreas, kidney, muscle, and humeral head. Extensive organ amyloid deposits were observed in active AL as well as in AL remission cohorts, and in both cardiac and noncardiac AL cohorts. Conclusion:18F-florbetapir PET/CT detected widespread organ amyloid deposition in subjects with both active AL and AL hematologic remission. In most instances, amyloid deposits in the various organs were not associated with clinical symptoms and, thus, were unrecognized. Early recognition of systemic organ involvement may help tailor treatment, and noninvasive monitoring of organ-level disease may guide management with novel fibril-resorbing therapies.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ehman EC, El-Sady MS, Kijewski MF, et al. Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET/CT. J Nucl Med. 2019. PMID: 30954943. doi:10.2967/jnumed.118.221770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。